The global enteral feeding formulas market was valued at USD 7,229.89 million in 2021. It is projected to reach USD 13,665.38 million by 2030, growing at a CAGR of 7.33% during the forecast period (2022-2030).The gastrointestinal tract is used in enteral feeding, and the formula can be given orally or through a feeding tube. Enteral nutrition/feeding is most commonly referred to as tube feeding. Tube feeding delivers nourishment and food to the body that can replace eating solid foods or following a typical diet. For patients with chronic illnesses, enteral feeding is typically prescribed by doctors and carried out under medical supervision. This method is typically advised for usage in people with specific gastrointestinal dysfunction formulas with added fiber and elements.
Get more information on this report Download Sample Report
Increasing Prevalence of Metabolic and Chronic Diseases
According to the World Health Organization (WHO), non-communicable diseases (NCDs), often chronic diseases, are responsible for 41 million deaths annually, or 71% of all fatalities globally. More than 15 million people between 30 and 69 die from an NCD yearly; 85% of these "premature" deaths occur in low- and middle-income countries. In addition, Americans having chronic diseases use healthcare facilities the most frequently. They are the leading cause of hospital admissions and prescription fillings. Cancer patients may likely experience malnutrition and gastrointestinal problems due to numerous medical procedures and therapies. Enteral feeding formulas' nutritionally supporting approach can help to reduce this issue.
Increasing Spending on Patient Care
The market for enteral feeding formulae is expected to rise due to rising spending on inpatient treatment and nutritional support for patients. Malnutrition is also a widespread issue that affects hospitalized patients all over the world. It prolongs hospital stays, increases mortality risk, and causes more complications. Healthcare spending is rising on patient care to reduce the risk of death and other consequences and the financial burden on patients. In most nations, healthcare spending is still increasing more quickly than GDP, continuing a long-term pattern. The largest share of GDP for healthcare spending has also been attributed to equitable, responsive, and effective health systems in North America, Europe, and the Asia-Pacific region.
Global governments, private foundations, and the worldwide community offer various funding options for therapeutic nutrition. The principal funding agencies are the National Institutes of Health, the US Department of Agriculture, the Robert Wood Johnson Foundation, and Nestle Foundation. The market is anticipated to have a robust CAGR over the forecast period as healthcare spending rises among the world's major economies.
Complications Associated with Enteral Nutrition
A small percentage of patients receiving enteral feeding support experience various difficulties, including sinusitis, nasal erosions, pharyngeal or esophageal perforation, cerebral or bronchial insertion, and gastrointestinal, mechanical, and metabolic issues. 20% of patients with gastrointestinal problems vomit and feel sick when fed through a tube. Patients who receive excessive doses of nutritional content may experience nausea, vomiting, abdominal cramping, and bloating. Aspiration, improper positioning of the tubes, and tube clogging are mechanical problems. A gastroenteric feeding tube's size and rigidity can occasionally cause gastroesophageal reflux and cause irritation or inflammation along its course. Staphylococcus aureus, Clostridium difficile, and fungus are a few of the often found microbes in the enteral feeding system utilized in residential settings. As a result, these issues restrict the use of enteral feeding, which restrains the market's expansion.
Entrance of New Products and Growing Innovation
In the last 25 years, the number and variety of enteral formulas available for use have increased dramatically. There are over 1,000 enteral formulas available, and companies are launching new products to cater to a broader range of clients. In order to meet the demand for nutritional food mix formulas for tube-fed patients, one such example is Abbott, which in 2019 introduced the PediaSure Harvest product and Ensure Harvest, a novel blend of real-food ingredients from sources such as mango, spinach, carrot, pumpkin, and banana. Furthermore, a recent study indicated the need for high-protein enteral nutrition formulas to cater to the energy demands of the critically ill, which indicates an opportunity in this market. Further innovation is also possible given the expanding knowledge of disease physiopathology, composition, and functionality of food ingredients. These opportunities present strong growth potential for companies.
The global enteral feeding formulas market is segmented by product, application, and end-users.
Based on product, the global enteral feeding formulas market is bifurcated into standard formulas and disease-specific formulas.
The standard formulas segment is the highest contributor to the market and is expected to grow at a CAGR of 7.24% during the forecast period. Standard formulas are the most frequently utilized category for patients needing tube feedings. The nutrient makeup of standard formulas is often created to correspond to that which is advised for healthy individuals. Additionally, several standard enteral feeding formulas are used as oral supplements and for tube feeding. Some of them have extra nutrients like fiber for bowel management and digestive health. Polymeric recipes, monomeric formulas, and other modular diets are examples of standard formulas. Polymeric formulae are appropriate for use in hospitals and home care since they are nutritionally packed and primarily comprised of nutrients that are still intact, which suggests a functioning digestive system. As a result, these formulations are frequently utilized following surgeries and for various ailments. The market expansion is anticipated to be boosted by recent product introductions and the widespread use of these formulae.
The market for disease-specific formulae is expected to develop over the projected period due to the rising prevalence of chronic diseases and the rising use of tailored nutritional supporting techniques. The specialized formulae for diseases such as diabetes, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), wound healing, chronic kidney disease (on and off dialysis), liver failure, and weakened immune systems are known as disease-specific formulas. Based on particular disease states, these items' macronutrient and micronutrient contents differ (e.g., very high protein for wound healing). According to the European Society for Clinical Nutrition and Metabolism's (ESPEN) Guidelines on Enteral Nutrition for Cancer Patients, depending on the gastrointestinal tract's level of function, supplemental or complete nutrition administered orally, enterally, or parenterally may be necessary if nutrient intake among cancer patients who are malnourished is insufficient.
Based on application, the global enteral feeding formulas market is bifurcated into oncology, neurology, critical care, diabetes, gastroenterology, and other applications.
The oncology segment owns the highest market share and is expected to grow at a CAGR of 7.61% during the forecast period. In many areas of cancer growth, nutrition is crucial and an essential supportive therapy during the entire course of cancer treatment. A cancer patient's quality of life can be improved, and their ability to maintain weight and lean body composition can be enhanced with adequate dietary support. Globally, the burden of cancer is rising quickly. The body's ability to manufacture non-essential compounds, such as vitamins, amino acids, and other chemicals involved in metabolic pathways, is compromised in cancer cases. Only one or two nutrients need to be supplemented to treat most of these disorders. As an illustration, vitamin D supplements can easily be used to treat vitamin D deficiency. Additionally, as it becomes exceedingly difficult for cancer patients to swallow food, supplying nourishment is essential for improving the clinical condition of cancer patients. Nutrition is given through enteral feeding tubes as the treatment progresses to help the patient keep their body mass.
The final step in treating Crohn's disease is mucosal repair, and enteral nutrition aids in stimulating gastrointestinal function. 60% to 80% of people with acute aggravation of Crohn's disease may experience remission. Additionally, the market is driven by increased demand for enteral feeding formula due to gastrointestinal illnesses. The prevalence of celiac disease was 0.4% in South America, 0.5% in Africa and North America, 0.6% in Asia, and 0.8% in Europe and Oceania in 2020, according to the Celiac Disease Foundation. The prevalence was much higher in children than adults, and it was higher in females than males. In conclusion, the majority of celiac disease varies with sex, age, and place. Even in developing nations, gastrointestinal disorders are rising due to unhealthy and irregular eating habits, sedentary lifestyles, stress, and cigarette use.
Based on end-user, the global enteral feeding formulas market is bifurcated into hospitals, home care agencies and hospices, and other end-users.
The hospital segment is the highest contributor to the market and is expected to grow at a CAGR of 7.61% during the forecast period. Enteral feeding is the most efficient method of delivering short- or long-term nutritional support for adult and pediatric hospital patients who cannot consume orally. Additionally, malnutrition is a recurrent issue in medical facilities and intensive care units worldwide. The licensed dietician is regarded as the expert in hospitals when it comes to choosing the right enteral formula, how administering it, keeping an eye on the patient, and solving any problems that may arise. In order to receive the necessary care, hospital admission rates have sharply increased due to the rising prevalence of cancer, diabetes, gastroenterological illnesses, and neurological diseases, fueling the growth of enteral feeding formula. The market for enteral feeding formula is expected to grow strongly due significantly to rising government efforts, increased healthcare service penetration, and an increase in the number of public and private institutions.
One of the markets for enteral feeding formulae that are expanding is home healthcare organizations and hospices. Patients who need ongoing enteral feeding care after being released from the hospital and placed in community settings are becoming more prevalent. Due to technological improvements, the development of percutaneous endoscopic gastrostomy procedures, and the change in care delivery from acute to community settings, the number of patients receiving home enteral tube feeding is increasing globally. A patient undergoing enteral tube feeding in a hospital or healthcare institution may be deemed to be discharged to their own home after they are recuperative stable. In order to minimize the adverse effects of home enteral feeding on the patient's quality of life, it is crucial to maintain enteral feeding plans tailored to the patient's specific needs. This includes the appropriateness of both pump and bolus feeding, the patient's daily routine, and the target nutritional intake for the patient as determined by the dietitian.
North America Dominates the Global Market
The global enteral feeding formulas market is bifurcated into four regions, namely North America, Europe, Asia-Pacific, and LAMEA.
Regional Growth Insights Request Sample Pages
North America is the most significant shareholder in the global enteral feeding formulas market and is expected to grow at a CAGR of 7.46% during the forecast period. The United States has a high incidence of chronic diseases like diabetes, cardiovascular disease, and kidney ailments. This, along with the country's burgeoning elderly population, significantly impacts the development of the market. Additionally, it is anticipated that the participation of important companies, like Victus Inc., Abbott Laboratories, Trovita Health Science, and Mead Johnson and Company LLC, will contribute to expanding the examined market in the nation. Therefore, the market is projected to grow in the United States due to high hospitalization rates, high inpatient care costs, and the growing burden of diseases in the nation. According to a report by the Public Health Agency of Canada 2020, more than 432,000 Canadians 65 and older had dementia with a diagnosis, including Alzheimer's. Enteral nourishment delivered using a Percutaneous Endoscopic Gastrostomy tube is a treatment option for long-term eating issues in neurodegenerative diseases that can enhance the quality of life and nutritional parameters.
Europe is expected to grow at a CAGR of 7.28%, generating USD 3,898.44 million during the forecast period. It is anticipated that the burden of chronic diseases will increase due to changing lifestyle habits among Germans, such as excessive sugar and carbs, physical inactivity, poor diet, etc. The development of the enteral feeding formulae market is anticipated to be aided by the numerous problems that have resulted from this, including cardiovascular diseases, diabetes, etc. Several businesses are offering enteral feeding formulae in Germany. For instance, the German company Fresenius Kabi AG provides a wide range of oral nutritional supplements (ONS), ready-to-use tube feeds, and powder products, including Fresubin (Standard), Fresubin DM, and Kabipro. The "French National Nutrition and Health Program (PNNS)" was put into place by the French government to enhance public health and lowering disease risk. As a result, the market for enteral feeding formulae is anticipated to develop over the projected period due to the rising incidence of diseases and government initiatives.
Asia-Pacific is expected to grow significantly during the forecast period. The rising prevalence of cancer and other chronic conditions in China, where patients are unable or unwilling to ingest food orally and need tube feeding, is one of the main drivers driving the expansion of the enteral feeding formula market. Due to the prevalence of numerous disorders in this area, the major market players are investing in development to take advantage of business opportunities. According to an article from the University of Health and Welfare in Niigata, Japan, published in May 2020, there are an estimated 140,000 cases of ulcerative colitis and 40,000 cases of Chron's disease in Japan, with the frequency of inflammatory bowel illnesses continuing to rise. The most effective nutritional therapy for Inflammatory Bowel Disease is enteral nutrition therapy, which is considered the gold standard (IBD).
Additionally, significant manufacturers are developing new product launches and requesting marketing authorization due to the market's increased adoption of enteral feeding formula. An Indian business called Dr. Reddys Laboratories Ltd. entered the hospital nutrition market by releasing their product, "Celevida Maxx." In India, this was done to help manage the nutritional needs of cancer, critical care, and COPD patients.
The rising prevalence of chronic diseases and the rising use of cutting-edge technology are projected to enhance market expansion in South Africa. Neonatal infants delivered before the 36th week of pregnancy typically have significant nutritional needs at this stage of development. They are generally fed enteral nutritional formulae using enteral feeding devices to match the high rates of nutrient deposition in newborns in the uterus. Therefore, the high prevalence of premature births in LAMEA is anticipated to be a crucial driver of market expansion. In Israel, cancer is one of the top causes of mortality, with 177.1 deaths per 100,000 people in 2018. These statistics, released by the Central Bureau of Statistics in Israel, demonstrate the strong demand for enteral cancer immunotherapy formulae.
The global enteral feeding formulas market’s major key players are. Abbott Laboratories, B. Braun Melsungen AG, Danone SA (Nutricia), FRESENIUS SE & CO. KGAA (Fresenius Kabi AG), Global Health Product Inc., Reckitt Benckiser Group plc. (Mead Johnson), Meiji Holdings Co. Ltd, Nestle SA, Trovita Health Science, and Victus Inc.